Advertisement

Archives of Gynecology and Obstetrics

, Volume 297, Issue 5, pp 1245–1253 | Cite as

Does post-operative radiochemotherapy improve survival in high-grade endometrial cancer patients? Results of a population-based cohort analysis of a cancer registry

  • Sophia Scharl
  • Thomas Papathemelis
  • Karin Kronberger
  • Michael Gerken
  • Anton Scharl
  • Oliver Kölbl
  • Monika Klinkhammer-Schalke
Gynecologic Oncology

Abstract

Purpose

Adjuvant treatment of high-grade endometrial cancer varies greatly due to the lack of definitive results from controlled randomized trials on the subject. In a retrospective study, we sought to investigate the influence of post-operative radio-, chemo, and radiochemotherapy on survival time and recurrence rates among high-grade endometrial cancer patients.

Methods

284 high-grade endometrial cancer patients (FIGOI–III, or unknown classification) diagnosed between 1998 and 2015 were retrospectively analyzed. All patients underwent surgery. Overall survival (OS), recurrence-free survival (RFS), and recurrence rates were compared for post-operative treatment modalities of radiotherapy alone (RT), chemotherapy alone (CTX), radiochemotherapy (RCT), and observation (OBS).

Results

Post-operative RCT and RT resulted in a significantly improved 5-year OS of 94.1% (HR 0.104, CI 0.013–0.809) and 62.1% (HR 0.615, CI 0.390–0.969), respectively, compared to 43.6% for OBS. CTX did not significantly improve OS leading to a 5-year OS of 56.5% (HR 0.783, CI 0.224–2.740). 5-year recurrence rate was lowest for patients treated with RCT (5.3%). 5-year RFS was 94.1% for the RCT group and proved to be significantly superior to 58.8% for RT (HR 9.034, CI 1.184–68.948), 56% for CTX (HR 12.738, CI 1.337–121.346), and 37.4% for OBS (HR 16.407, CI 2.127–126.575), respectively. In comparison with OBS, RT alone resulted in a significant improvement in RFS (HR 0.551, CI 0.354–0.856).

Conclusions

Our retrospective population-based study indicates a survival benefit from treating high-grade endometrial cancer with post-operative RCT. Randomized controlled trials are needed to minimize potential confounding parameters and further clarify the subject.

Keywords

Endometrial cancer Radiotherapy Chemotherapy Adjuvant treatment 

Notes

Author’s contributions

Protocol/project development: Scharl S, Papathemelis T, Scharl A, Kölbl O, and Klinkhammer-Schalke M. Data collection or management: Kronberger K and Gerken M. Data analysis: Kronberger K, Gerken M, and Scharl S. Manuscript draft: Scharl S. Manuscript revision: Papathemelis T, Scharl A, Kölbl O, and Klinkhammer-Schalke M

Funding

No funding was obtained

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

Ethics approval and consent to participate: due to the analysis of data from a clinical cancer registry, no ethics approval was necessary. This was confirmed by the Ethics Committee at the Regensburg University, Regensburg, Germany.

References

  1. 1.
    A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102. http://meetinglibrary.asco.org/record/98495/abstract. Zugriff am 4.6.2017
  2. 2.
    Ayeni TA, Bakkum-Gamez JN, Mariani A et al (2013) Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol 129(3):478–485CrossRefPubMedGoogle Scholar
  3. 3.
    Bernardini MQ, Gien LT, Lau S et al (2016) Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 141(1):148–154CrossRefPubMedGoogle Scholar
  4. 4.
    Blake P, Swart AM, Orton J et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373(9658):137–146CrossRefPubMedGoogle Scholar
  5. 5.
    de Boer SM, Powell ME, Mileshkin L et al (2016) Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3). Lancet Oncol 17(8):1114–1126CrossRefPubMedGoogle Scholar
  6. 6.
    Buhtoiarova TN, Brenner CA, Singh M (2016) Endometrial carcinoma: role of current and emerging biomarkers in resolving persistent clinical dilemmas. Am J Clin Pathol 145(1):8–21CrossRefPubMedGoogle Scholar
  7. 7.
    Creutzberg CL, Nout RA, Lybeert MLM et al (2011) Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81(4):e631–e638CrossRefPubMedGoogle Scholar
  8. 8.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRefPubMedGoogle Scholar
  9. 9.
    Hamilton CA, Cheung MK, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hogberg T, Signorelli M, de Oliveira CF et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 46(13):2422–2431CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92(3):744–751CrossRefPubMedGoogle Scholar
  12. 12.
    Koh W-J, Greer B, Abu-Rustum N, Campos SM. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Uterine Neoplasms. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Zugriff am 14.5.2017
  13. 13.
    Marnitz S, Köhler C (2012) Current therapy of patients with endometrial carcinoma. A critical review. Strahlenther Onkol 188(1):12–20CrossRefPubMedGoogle Scholar
  14. 14.
    Miao J-W, Deng X-H (2012) High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy. Chin J Cancer Res 24(4):332–339CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nout RA, Smit V, Putter H et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2). The Lancet 375(9717):816–823CrossRefGoogle Scholar
  16. 16.
    Pelvic radiation therapy or vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk Stage I or Stage II endometrial cancer—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00807768. Zugriff am 31.5.2017
  17. 17.
    Reynaers EAEM, Ezendam NPM, Pijnenborg JMA (2015) Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer. J Surg Oncol 111(6):790–794CrossRefPubMedGoogle Scholar
  18. 18.
    Selective targeting of adjuvant therapy for endometrial cancer (STATEC)—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02566811. Zugriff am 31.5.2017
  19. 19.
    Selective targeting of adjuvant therapy for endometrial cancer (STATEC)—tabular view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/record/NCT02566811. Zugriff am 23.1.2017
  20. 20.
    Signorelli M, Lissoni AA, de Ponti E et al (2015) Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer. J Gynecol Oncol 26(4):284–292CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sorosky JI (2012) Endometrial cancer. Obstet Gynecol 120(2 Pt 1):383–397CrossRefPubMedGoogle Scholar
  22. 22.
    Sozen H, Ciftci R, Vatansever D et al (2016) Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma. Aust N Z J Obstet Gynaecol 56(2):199–206CrossRefPubMedGoogle Scholar
  23. 23.
    Voss MA, Ganesan R, Ludeman L et al (2012) Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 124(1):15–20CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik und Poliklinik für Strahlentherapie und RadioOnkologie, Klinikum rechts der IsarTechnische Universität München (TUM)MunichGermany
  2. 2.FrauenklinikAmbergGermany
  3. 3.Tumorzentrum Regensburg, Institut für Qualitätssicherung und Versorgungsforschung der, Universität RegensburgRegensburgGermany
  4. 4.Klinik und Poliklinik für StrahlentherapieUniversitätsklinikum RegensburgRegensburgGermany

Personalised recommendations